Key result
Combination anthracycline-containing chemotherapy in breast cancer patients was associated with an increase in cfPWV by 0.95 m/s per year, indicating accelerated vascular wall aging.
Why the study?
To identify and analyze changes in arterial stiffness parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy.
Does combination anthracycline-containing chemotherapy alter arterial stiffness parameters in women with breast cancer?
Cohort (n=50)
Does combination anthracycline-containing chemotherapy alter arterial stiffness parameters in women with breast cancer?
Effect estimate: increase of 0.95 m/s per year
p-value: p=<0.05
Anthracycline-containing chemotherapy in breast cancer patients is associated with an increase in arterial stiffness over 48 weeks, indicating accelerated vascular aging and potential increased cardiovascular risk.
Aim. To identify and analyze changes of arterial stiffness (AS) parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy (ACCT). Material and methods. Fifty women with verified breast cancer aged 46,7±7 years with indications for combined ACCT were assessed for AS (carotid-femoral pulse wave velocity (cfPWV) (m/s); cardio-ankle vascular index (CAVI); cardio-ankle pulse wave velocity (caPWV) (m/s); β-stiffness index, novel Russian Stelari and haStart indices) at 4 visits as follows: before ACCT, after 8-12, 20-24 and 48 weeks from the ACCT start. Results. A reliable decrease in cfPWV was revealed at visit 2 (7,48±1,51, p<0,05) and visit 3 (8,34±1,66, p<0,05) with further significant increase at visit 4 when compared with baseline data. Similar reliable changes were demonstrated for the Stelari index. CAVI decreased at visits 2 and 3 with a reliable difference from the values at visits 1 and 4. No reliable changes in β and haStart stiffness indices were obtained during the follow-up period. Conclusion. In patients with breast cancer who underwent combined ACCT, an increase in cfPWV by 0,95 m/s per year was revealed, which indicates accelerated vascular wall aging and a possible increase in cardiovascular risk in this category of patients.
No takes yet. Share an insight, caveat, or question.
Medvedeva et al. (2025) conducted a cohort in breast cancer (n=50). Combination anthracycline-containing chemotherapy (ACCT) vs. Baseline (before ACCT) was evaluated on Carotid-femoral pulse wave velocity (cfPWV) (increase of 0.95 m/s per year, p=<0.05). Combination anthracycline-containing chemotherapy in breast cancer patients was associated with an increase in cfPWV by 0.95 m/s per year, indicating accelerated vascular wall aging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: